Top

Published in:

01-03-2022 | Hypercholesterolemia | Neurology and Preclinical Neurological Studies - Original Article

Executive functioning and serum lipid fractions in Parkinson’s disease—a possible sex-effect: the PACOS study

Authors: Antonina Luca, Roberto Monastero, Calogero Edoardo Cicero, Roberta Baschi, Giulia Donzuso, Giovanni Mostile, Vincenzo Restivo, Lucia Di Giorgi, Maria Caccamo, Mario Zappia, Alessandra Nicoletti

Published in: Journal of Neural Transmission | Issue 3/2022

Abstract

The association between dyslipidemia and cognitive performance in Parkinson’s disease (PD) patients still needs to be clarified. Aim of the study was to evaluate the presence of possible associations between serum lipids fractions and executive dysfunction also exploring the sex-specific contribute of lipids level on cognition. Patients from the PACOS cohort, who underwent a complete serum lipid profile measures (total cholesterol-TC, low-density lipoprotein cholesterol-LDL, high-density lipoprotein cholesterol-HDL and triglycerides-TG) were selected. Adult Treatment Panel III guidelines of the National Cholesterol Education Program were used to classify normal/abnormal lipid fractions. Executive functioning was assessed with the Frontal Assessment Battery (FAB). Logistic regression was performed to assess associations between lipids fractions and FAB score. Correlations between lipids fractions and FAB score were explored. Sex-stratified analysis was performed. Three hundred and forty-eight PD patients (148 women; age 66.5 ± 9.5 years; disease duration 3.9 ± 4.9 years) were enrolled. Women presented significantly higher TC, LDL and HDL than men. In the whole sample, any association between lipid profile measures and FAB score was found. Among women, a positive association between hypertriglyceridemia and FAB score under cutoff was found (OR 3.4; 95%CI 1.29–9.03; p value 0.013). A statistically significant negative correlation was found between the FAB score and triglyceride serum levels (r = − 0.226; p value 0.005). Differently, among men, a statistically significant negative association between hypercholesterolemia and FAB score under cutoff (OR 0.4; 95%CI 0.17–0.84; p value 0.018) and between high LDL levels and FAB score under cutoff (OR 0.4; 95%CI 0.18–0.90; p value 0.027) were found. Our data suggest a sex-specific different role of lipids in executive functioning.

Appollonio I, Leone M, Isella V, Piamarta F, Consoli T, Villa ML, Forapani E, Russo A, Nichelli P (2005) The Frontal Assessment Battery (FAB): normative values in an Italian population sample. Neurol Sci 26:108–116. https://doi.org/10.1007/s10072-005-0443-4CrossRefPubMed

Bakeberg MC, Gorecki AM, Kenna JE, Jefferson A, Byrnes M, Ghosh S, Horne MK, Mcgregor S, Stell R, Walters S, Mastaglia FL, Anderton RS (2021) Elevated HDL levels linked to poorer cognitive ability in females with Parkinson’s disease. Front Aging Neurosci. https://doi.org/10.3389/fnagi.2021.656623CrossRefPubMedPubMedCentral

Banks WA (2012) Role of the blood-brain barrier in the evolution of feeding and cognition. Ann NY Acad Sci 1264:13–19. https://doi.org/10.1111/j.1749-6632.2012.06568.xCrossRefPubMed

Baschi R, Restivo V, Nicoletti A, Cicero CE, Luca A, Recca D, Zappia M, Monastero R (2019) Mild behavioral impairment in parkinson’s disease: data from the PArkinson’s Disease COgnitive Impairment Study. J Alzheimer Dis 68:1603–1610. https://doi.org/10.1016/j.parkreldis.2019.03.027CrossRef

Bernath MM, Bhattacharyya S, Nho K, Barupal DK, Fiehn O, Baillie R, Risacher SL, Arnold M, Jacobson T, Trojanowski JQ, Shaw LM, Weiner MW, Doraiswamy PM, Kaddurah-Daouk R, Saykin AJ (2020) Alzheimer’s disease neuroimaging initiative and Alzheimer’s disease metabolomics consortium. Serum triglycerides in Alzheimer disease: Relation to neuroimaging and CSF biomarkers. Neurology. https://doi.org/10.1212/WNL.0000000000009436CrossRefPubMedPubMedCentral

Choe CU, Petersen E, Lezius S, Cheng B, Schulz R, Buhmann C, Pötter-Nerger M, Daum G, Blankenberg S, Gerloff C, Schwedhelm E, Zeller T (2021) Association of lipid levels with motor and cognitive function and decline in advanced Parkinson’s disease in the Mark-PD study. Parkinsonism Relat Disord 85:5–10. https://doi.org/10.1016/j.parkreldis.2021.02.007CrossRefPubMed

Cicero CE, Raciti L, Monastero R, Mostile G, Donzuso G, Sciacca G, Luca A, Terravecchia C, Giuliano L, Baschi R, Davì M, Zappia M, Nicoletti A (2019) Cardiovascular autonomic function and MCI in Parkinson’s disease. Parkinsonism Relat Disord 69:55–58. https://doi.org/10.1016/j.parkreldis.2019.10.023CrossRefPubMed

Donzuso G, Monastero R, Cicero CE, Luca A, Mostile G, Giuliano L, Baschi R, Caccamo M, Gagliardo C, Palmucci S, Zappia M, Nicoletti A (2021) Neuroanatomical changes in early Parkinson’s disease with mild cognitive impairment: a VBM study; the Parkinson’s Disease Cognitive Impairment Study (PaCoS). Neurol Sci 42:3723–3731. https://doi.org/10.1007/s10072-020-05034-9CrossRefPubMed

Executive summary of the third report of the National Cholesterol Education Program (NCEP) (2001) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486–2497. https://doi.org/10.1001/jama.285.19.2486

Fang C, Lv L, Mao S, Dong H, Liu B (2020) Cognition deficits in Parkinson’s disease: mechanisms and treatment. Parkinsons Dis. https://doi.org/10.1155/2020/2076942CrossRefPubMedPubMedCentral

Fu X, Wang Y, He X, Li H, Liu H, Zhang X (2020) A systematic review and meta-analysis of serum cholesterol and triglyceride levels in patients with Parkinson’s disease. Lipids Health Dis 19:97. https://doi.org/10.1186/s12944-020-01284-wCrossRefPubMedPubMedCentral

Gibb WR, Lees AJ (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 51:745–752. https://doi.org/10.1136/jnnp.51.6.745CrossRefPubMedPubMedCentral

Guo Y, Xu W, Liu FT, Li JQ, Cao XP, Tan L, Wang J, Yu JT (2019) Modifiable risk factors for cognitive impairment in Parkinson’s disease: a systematic review and meta-analysis of prospective cohort studies. Mov Disord 34:876–883. https://doi.org/10.1002/mds.27665CrossRefPubMed

Huang X, Ng SY, Chia NS, Acharyya S, Setiawan F, Lu Z, Tan YT, Ng E, Wen MC, Ng ASL, Tay KY, Au WL, Tan EK, Tan LC (2018) Higher serum triglyceride levels are associated with Parkinson’s disease mild cognitive impairment. Mov Disord 33:1970–1971. https://doi.org/10.1002/mds.27521CrossRefPubMed

Iwaki H, Blauwendraat C, Leonard HL, Makarious MB, Kim JJ, Liu G, Maple-Grødem J, Corvol JC, Pihlstrøm L, van Nimwegen M, Smolensky L, Amondikar N, Hutten SJ, Frasier M, Nguyen KH, Rick J, Eberly S, Faghri F, Auinger P, Scott KM, Wijeyekoon R, Van Deerlin VM, Hernandez DG, Gibbs RJ, Day-Williams AG, Brice A, Alves G, Noyce AJ, Tysnes OB, Evans JR, Breen DP, Estrada K, Wegel CE, Danjou F, Simon DK, Andreassen OA, Ravina B, Toft M, Heutink P, Bloem BR, Weintraub D, Barker RA, Williams-Gray CH, van de Warrenburg BP, Van Hilten JJ, Scherzer CR, Singleton AB, Nalls MA (2021) Differences in the presentation and progression of Parkinson’s disease by sex. Mov Disord 36:106–117. https://doi.org/10.1002/mds.28312CrossRefPubMed

Knopp RH, Paramsothy P, Retzlaff BM, Fish B, Walden C, Dowdy A, Tsunehara C, Aikawa K, Cheung MC (2006) Sex differences in lipoprotein metabolism and dietary response: basis in hormonal differences and implications for cardiovascular disease. Curr Cardiol Rep 8:452–459. https://doi.org/10.1007/s11886-006-0104-0CrossRefPubMed

Kurlawala Z, Shadowen PH, McMillan JD, Beverly LJ, Friedland RP (2021) Progression of nonmotor symptoms in Parkinson’s disease by sex and motor laterality. Parkinsons Dis. https://doi.org/10.1155/2021/8898887CrossRefPubMedPubMedCentral

Lima CF, Meireles LP, Fonseca R, Castro SL, Garrett C (2008) The Frontal Assessment Battery (FAB) in Parkinson’s disease and correlations with formal measures of executive functioning. J Neurol 255:1756–1761. https://doi.org/10.1007/s00415-008-0024-6CrossRefPubMed

Lu Y, An Y, Yu H, Che F, Zhang X, Rong H, Xi Y, Xiao R (2017) Sex-specific nonlinear associations between serum lipids and different domains of cognitive function in middle to older age individuals. Metab Brain Dis 32:1089–1097. https://doi.org/10.1007/s11011-017-9999-yCrossRefPubMed

Luca A, Monastero R, Baschi R, Cicero CE, Mostile G, Davì M, Restivo V, Zappia M, Nicoletti A (2021) Cognitive impairment and levodopa induced dyskinesia in Parkinson’s disease: a longitudinal study from the PACOS cohort. Sci Rep 11:867. https://doi.org/10.1038/s41598-020-79110-7CrossRefPubMedPubMedCentral

Mollenhauer B, Zimmermann J, Sixel-Doring F, Focke NK, Wicke T, Ebentheuer J, Schaumburg M, Lang E, Friede T, Trenkwalder G (2019) DeNoPa Study Baseline predictors for progression 4 years after Parkinson’s disease diagnosis in the de novo Parkinson cohort (DeNoPa). Mov Disord 34:67–77. https://doi.org/10.1002/mds.27492CrossRefPubMed

Monastero R, Cicero CE, Baschi R, Davì M, Luca A, Restivo V, Zangara C, Fierro B, Zappia M, Nicoletti A (2018) Mild cognitive impairment in Parkinson’s disease: the Parkinson’s disease cognitive study (PACOS). J Neurol 265:1050–1058. https://doi.org/10.1007/s00415-018-8800-4CrossRefPubMed

Mostile G, Giuliano L, Monastero R, Luca A, Cicero CE, Donzuso G, Dibilio V, Baschi R, Terranova R, Restivo V, Sofia V, Zappia M, Nicoletti A (2019) Electrocortical networks in Parkinson’s disease patients with mild cognitive impairment. The PaCoS study. Parkinsonism Relat Disord 64:156–162. https://doi.org/10.1016/j.parkreldis.2019.03.027CrossRefPubMed

Nicoletti A, Vasta R, Mostile G, Nicoletti G, Arabia G, Iliceto G, Lamberti P, Marconi R, Morgante L, Barone P, Quattrone A, Zappia M (2017) Gender effect on non-motor symptoms in Parkinson’s disease: are men more at risk? Parkinsonism Relat Disord 35:69–74. https://doi.org/10.1016/j.parkreldis.2016.12.008CrossRefPubMed

Nicoletti A, Luca A, Baschi R, Cicero CE, Mostile G, Davì M, Pilati L, Restivo V, Zappia M, Monastero R (2019) Incidence of mild cognitive impairment and dementia in Parkinson’s disease: the Parkinson’s disease cognitive impairment study. Front Aging Neurosci 11:21. https://doi.org/10.3389/fnagi.2019.00021CrossRefPubMedPubMedCentral

Nicoletti A, Luca A, Baschi R, Cicero CE, Mostile G, Davì M, La Bianca G, Restivo V, Zappia M, Monastero R (2021) Vascular risk factors, white matter lesions and cognitive impairment in Parkinson’s disease: the PACOS longitudinal study. J Neurol 268:549–558. https://doi.org/10.1007/s00415-020-10189-8CrossRefPubMed

Parthasarathy V, Frazier DT, Bettcher BM, Jastrzab L, Chao L, Reed B, Mungas D, Weiner M, DeCarli C, Chui H, Kramer JH (2017) Triglycerides are negatively correlated with cognitive function in nondemented aging adults. Neuropsychology 31:682–688. https://doi.org/10.1037/neu0000335CrossRefPubMedPubMedCentral

Potashkin J, Huang X, Becker C, Chen H, Foltynie T, Marras C (2020) Understanding the links between cardiovascular disease and Parkinson’s disease. Mov Disord 35:55–74. https://doi.org/10.1002/mds.27836CrossRefPubMed

Sáiz-Vazquez O, Puente-Martínez A, Ubillos-Landa S, Pacheco-Bonrostro J, Santabárbara J (2020) Cholesterol and Alzheimer’s disease risk: a meta-meta-analysis. Brain Sci 10:386. https://doi.org/10.3390/brainsci10060386CrossRefPubMedCentral

Sterling NW, Lichtenstein M, Lee EY, Lewis MM, Evans A, Eslinger PJ, Du G, Gao X, Chen H, Kong L, Huang X (2016) Higher plasma LDL-cholesterol is associated with preserved executive and fine motor functions in Parkinson’s disease. Aging Dis 7:237–245. https://doi.org/10.14336/AD.2015.1030CrossRefPubMedPubMedCentral

Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25:2649–2653. https://doi.org/10.1002/mds.23429CrossRefPubMed

Title: Executive functioning and serum lipid fractions in Parkinson’s disease—a possible sex-effect: the PACOS study
Authors: Antonina Luca
Roberto Monastero
Calogero Edoardo Cicero
Roberta Baschi
Giulia Donzuso
Giovanni Mostile
Vincenzo Restivo
Lucia Di Giorgi
Maria Caccamo
Mario Zappia
Alessandra Nicoletti
Publication date: 01-03-2022
Publisher: Springer Vienna
Keywords: Hypercholesterolemia
Parkinson's Disease
Published in: Journal of Neural Transmission / Issue 3/2022
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-022-02460-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Executive functioning and serum lipid fractions in Parkinson’s disease—a possible sex-effect: the PACOS study

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2022

Pivotal role of obliquus capitis inferior in torticaput revealed by single-photon emission computed tomography

Parkinson's disease patients with freezing of gait have more severe voice impairment than non-freezers during “ON state”

Electroconvulsive therapy and adiposity-related parameters in treatment-resistant depressed patients

Increased hair cortisol in mothers of children with ADHD symptoms and psychosocial adversity background

Serum NfL and CHI3L1 for ALS and parkinsonian disorders in the process of diagnosis

5-HTT genotype and inertia of negative affect in adolescents and young adults from the general population